Clinical features of ALK+ versus ALK− ALCL, systemic type
| Clinical feature . | ALK+ . | ALK− . | P* . | PTCL-NOS . | P† . |
|---|---|---|---|---|---|
| Total no. patients (%) | 87 (55) | 72 (45) | 331 | ||
| Median age, y | 34 | 58 | < .001 | 57 | .30 |
| Age less than 60 y, no. (%) | 74 (86) | 42 (58) | < .001 | 170 (50) | .21 |
| Male-female ratio | 1.7:1 | 1.5:1 | .74 | 1.9:1 | .41 |
| Stage, no. (%) | |||||
| II | 30 (35) | 30 (42) | .38 | 102 (31) | .18 |
| III | 25 (29) | 15 (21) | 87 (26) | ||
| IV | 31 (36) | 27 (37) | 145 (43) | ||
| Elevated LDH, no. (%) | 31 (37) | 31 (46) | .28 | 158 (49) | .62 |
| Performance status over 2, no. (%) | 30 (35) | 21 (30) | .56 | 60 (18) | .02 |
| Nodal only disease, no. (%) | 39 (54) | 38 (49) | .52 | 124 (42) | .07 |
| Extranodal sites more than 1, no. (%) | 17 (19.5) | 15 (21) | .84 | 99 (29) | .15 |
| Bulky disease more than 10 cm, no. (%) | 17 (21) | 6 (11) | .17 | 19 (7) | .25 |
| B symptoms, no. (%) | 52 (60) | 41 (57) | .72 | 118 (35) | < .001 |
| Hemoglobin less than 110 g/L, no. (%) | 17 (27) | 18 (32) | .54 | 61 (22) | .11 |
| Platelets less than 150 × 109/L, no. (%) | 6 (10) | 6 (11) | .83 | 64 (24) | .03 |
| IPI score, no. (%) | |||||
| 0,1 | 40 (49) | 27 (41) | .50 | 88 (28) | .066 |
| 2 | 18 (22) | 13 (20) | 111 (35) | ||
| 3 | 12 (15) | 16 (24) | 71 (22) | ||
| 4,5 | 12 (14) | 10 (15) | 48 (15) | ||
| 5-y FFS, % | 60 | 36 | .015 | 20 | .012 |
| 5-y OS, % | 70 | 49 | .016 | 32 | .032 |
| 5-y FFS by IPI, % | |||||
| 0,1 | 80 | 62 | 35 | ||
| 2 | 61 | 44 | .002‡ | 16 | < .001‡ |
| 3 | 23 | 16 | 13 | ||
| 4,5 | 25 | 13 | 8 | ||
| 5-y OS by IPI, % | |||||
| 0,1 | 90 | 74 | 52 | ||
| 2 | 68 (P< .001‡) | 62 | < .001‡ | 33 | < .001‡ |
| 3 | 23 | 31 | 16 | ||
| 4,5 | 33 | 13 | 13 | ||
| Clinical feature . | ALK+ . | ALK− . | P* . | PTCL-NOS . | P† . |
|---|---|---|---|---|---|
| Total no. patients (%) | 87 (55) | 72 (45) | 331 | ||
| Median age, y | 34 | 58 | < .001 | 57 | .30 |
| Age less than 60 y, no. (%) | 74 (86) | 42 (58) | < .001 | 170 (50) | .21 |
| Male-female ratio | 1.7:1 | 1.5:1 | .74 | 1.9:1 | .41 |
| Stage, no. (%) | |||||
| II | 30 (35) | 30 (42) | .38 | 102 (31) | .18 |
| III | 25 (29) | 15 (21) | 87 (26) | ||
| IV | 31 (36) | 27 (37) | 145 (43) | ||
| Elevated LDH, no. (%) | 31 (37) | 31 (46) | .28 | 158 (49) | .62 |
| Performance status over 2, no. (%) | 30 (35) | 21 (30) | .56 | 60 (18) | .02 |
| Nodal only disease, no. (%) | 39 (54) | 38 (49) | .52 | 124 (42) | .07 |
| Extranodal sites more than 1, no. (%) | 17 (19.5) | 15 (21) | .84 | 99 (29) | .15 |
| Bulky disease more than 10 cm, no. (%) | 17 (21) | 6 (11) | .17 | 19 (7) | .25 |
| B symptoms, no. (%) | 52 (60) | 41 (57) | .72 | 118 (35) | < .001 |
| Hemoglobin less than 110 g/L, no. (%) | 17 (27) | 18 (32) | .54 | 61 (22) | .11 |
| Platelets less than 150 × 109/L, no. (%) | 6 (10) | 6 (11) | .83 | 64 (24) | .03 |
| IPI score, no. (%) | |||||
| 0,1 | 40 (49) | 27 (41) | .50 | 88 (28) | .066 |
| 2 | 18 (22) | 13 (20) | 111 (35) | ||
| 3 | 12 (15) | 16 (24) | 71 (22) | ||
| 4,5 | 12 (14) | 10 (15) | 48 (15) | ||
| 5-y FFS, % | 60 | 36 | .015 | 20 | .012 |
| 5-y OS, % | 70 | 49 | .016 | 32 | .032 |
| 5-y FFS by IPI, % | |||||
| 0,1 | 80 | 62 | 35 | ||
| 2 | 61 | 44 | .002‡ | 16 | < .001‡ |
| 3 | 23 | 16 | 13 | ||
| 4,5 | 25 | 13 | 8 | ||
| 5-y OS by IPI, % | |||||
| 0,1 | 90 | 74 | 52 | ||
| 2 | 68 (P< .001‡) | 62 | < .001‡ | 33 | < .001‡ |
| 3 | 23 | 31 | 16 | ||
| 4,5 | 33 | 13 | 13 | ||